Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bone cancer.
Biermann JS, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Butrynski JE, Cheong D, Chow W, Curry WT, Frassica DA, Frassica FJ, Hande KR, Hornicek FJ, Jones RL, Mayerson J, McGarry SV, McGrath B, Morris CD, O'Donnell RJ, Randall RL, Santana VM, Satcher RL, Siegel HJ, von Mehren M, Bergman MA, Sundar H; National complrehensive cancer network. Biermann JS, et al. Among authors: agulnik m. J Natl Compr Canc Netw. 2013 Jun 1;11(6):688-723. doi: 10.6004/jnccn.2013.0088. J Natl Compr Canc Netw. 2013. PMID: 23744868
Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center.
Nonzee NJ, Dandade NA, Patel U, Markossian T, Agulnik M, Argiris A, Patel JD, Kern RC, Munshi HG, Calhoun EA, Bennett CL. Nonzee NJ, et al. Among authors: agulnik m. Cancer. 2008 Sep 15;113(6):1446-52. doi: 10.1002/cncr.23714. Cancer. 2008. PMID: 18683883 Free article.
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG. Schwartz GK, et al. Among authors: agulnik m. Lancet Oncol. 2013 Apr;14(4):371-82. doi: 10.1016/S1470-2045(13)70049-4. Epub 2013 Mar 8. Lancet Oncol. 2013. PMID: 23477833 Free PMC article. Clinical Trial.
Occult primary, version 3.2014.
Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Schwab RB, Shulman LN, Smerage JB, Stevenson MM, Varadhachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass DA; National Comprehensive Cancer Network. Ettinger DS, et al. Among authors: agulnik m. J Natl Compr Canc Netw. 2014 Jul;12(7):969-74. doi: 10.6004/jnccn.2014.0093. J Natl Compr Canc Netw. 2014. PMID: 24994917
Targeted therapies in advanced differentiated thyroid cancer.
Carneiro RM, Carneiro BA, Agulnik M, Kopp PA, Giles FJ. Carneiro RM, et al. Among authors: agulnik m. Cancer Treat Rev. 2015 Sep;41(8):690-8. doi: 10.1016/j.ctrv.2015.06.002. Epub 2015 Jun 17. Cancer Treat Rev. 2015. PMID: 26105190 Review.
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK. Tap WD, et al. Among authors: agulnik m. Lancet. 2016 Jul 30;388(10043):488-97. doi: 10.1016/S0140-6736(16)30587-6. Epub 2016 Jun 9. Lancet. 2016. PMID: 27291997 Free PMC article. Clinical Trial.
NCCN Guidelines Insights: Bone Cancer, Version 2.2017.
Biermann JS, Chow W, Reed DR, Lucas D, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Budd GT, Curry WT, Didwania A, Fabbri N, Hornicek FJ, Kuechle JB, Lindskog D, Mayerson J, McGarry SV, Million L, Morris CD, Movva S, O'Donnell RJ, Randall RL, Rose P, Santana VM, Satcher RL, Schwartz H, Siegel HJ, Thornton K, Villalobos V, Bergman MA, Scavone JL. Biermann JS, et al. Among authors: agulnik m. J Natl Compr Canc Netw. 2017 Feb;15(2):155-167. doi: 10.6004/jnccn.2017.0017. J Natl Compr Canc Netw. 2017. PMID: 28188186
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).
Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC. Ma BBY, et al. Among authors: agulnik m. J Clin Oncol. 2018 May 10;36(14):1412-1418. doi: 10.1200/JCO.2017.77.0388. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584545 Free PMC article. Clinical Trial.
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1.
Chawla SP, Van Tine BA, Pollack SM, Ganjoo KN, Elias AD, Riedel RF, Attia S, Choy E, Okuno SH, Agulnik M, von Mehren M, Livingston MB, Keedy VL, Verschraegen CF, Philip T, Bohac GC, Yurasov S, Yakovich A, Lu H, Chen M, Maki RG. Chawla SP, et al. Among authors: agulnik m. J Clin Oncol. 2022 Apr 20;40(12):1291-1300. doi: 10.1200/JCO.20.03452. Epub 2021 Jul 14. J Clin Oncol. 2022. PMID: 34260265 Clinical Trial.
Evolving strategies for management of desmoid tumor.
Riedel RF, Agulnik M. Riedel RF, et al. Among authors: agulnik m. Cancer. 2022 Aug 15;128(16):3027-3040. doi: 10.1002/cncr.34332. Epub 2022 Jun 7. Cancer. 2022. PMID: 35670122 Free PMC article. Review.
114 results